Elite Pharmaceuticals (ELTP +9.5%) settles its claims with Novel Laboratories and other parties regarding the termination of their Strategic Alliance Agreement. In addition, the parties paid Elite $5M for 9,800 shares of Novel Class A common stock. This resolves all disputes and claims between the parties and ends Elite's ownership in Novel.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs